Market Newsdesk

NEW YORK, NY, March 26, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced the upcoming commercial launch of its enhanced, 25mg Cannabidiol (“CBD”) & Cannabigerol (“CBG”) infused, version of Tauri-Gum™.  This 25mg product version will be available on E-Commerce (www.taurigum.com), on Stock Up Express (www.stockupexpress.com), in gas station convenience marts, in dispensaries, in supermarkets, in select medical practices, in a diverse setting of retail locations, and internationally.  The Company is highly confident in the future prospects of its flagship Tauri-Gum™ brand.   

The infusion concentrations of the following 5 Tauri-Gum™ SKUs have been increased to 25mg/each piece of chewing gum– – [3 SKUs] CBD Infused (Mint, Blood Orange, Pomegranate) / [2 SKUs] CBG Infused (Peach-Lemon, Black Currant).  

The Company has made the following strategic decision: There will be No Increase in Tauri-Gum™ Retail Prices (“MSRP”).  The Company has been successful in reducing costs (basic factors of production costs), pursuant to the Tauri-Gum™ manufacturing process.    

Lastly, the Company has been in multiple discussions and negotiations for potential Partnerships, both domestically and internationally.  The Company will update shareholders in a timely manner, should any material Agreement(s) be consummated.  

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.

The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

There can be no guarantees that any Partnership(s) or Agreement(s) will ultimately be consummated.

Contact:

Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: [email protected]

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @sethsms47

Twitter: @SethMShaw

Corp. Website:   www.tauriga.com

E-Commerce Website:  www.taurigum.com

WISeKey $WKEY to Auction the First Ever Secure Luxury Non–Fungible Token #NFT Watch on March 31, 2021

WISeKey’s WISe.ART NFTs are already trading using a peer-to-peer marketplace for trusted exclusive digital items and crypto luxury collectibles. For more information visit OpenSea NFT MarketPlace at https://opensea.io/accounts/WISeArt.

Watch demo video of the WIS.Watch NFT
activation at


https://youtu.be/CSIqLT0Ucpg

.

WISeKey’s CEO, Carlos Moreira will appear on Benzinga’s ‘Power Hour’ to discuss WISeKey’s NFT technology, today at 1:30 p.m. ET

Geneva, Switzerland – March 26, 2021 – WISeKey International Holding Ltd (SIX: WIHN, NASDAQ: WKEY), a Swiss based cyber security, IoT, AI platform company, today announced that it will auction the first ever secure luxury NFT watch on March 31, 2021, using Open.Sea NFT MarketPlace. The highest bidder will receive the high-end NFT watch with an embedded digital certificate using a secure element with a cryptographic public‑private key pair unique to each watch.

WISeKey is launching this auction to demonstrate its technology and encourage luxury watch brands to start using it to auction their high-end watches through WIS.Watch NFTs. The company successfully launched this week its WISe.Art, a digital certificate of authenticity, a NFT for art pieces that will live forever on the blockchain, unchanged and unchallengeable, as proof of the buyer’s ownership. This announcement generated strong interest from the luxury and art community and WISe.ART is now operation using OpenSea NFT MarketPlace – https://opensea.io/accounts/WISeArt.

This method secures watches using cutting-edge authentication microprocessors combined with identity blockchain technology, which together with on-the-ground measures ensures the authenticity of the artwork. See video  https://youtu.be/CSIqLT0Ucpg.

A WISeKey NFT is a unit of data on the blockchain, where each NFT represents a unique digital item, such as an artwork, audio, video, an item in video games or other forms of creative work. While digital files themselves are infinitely reproducible, NFTs representing them are traced on their underlying blockchains and provide buyers with proof of ownership.  Blockchains such as Ethereum, Bitcoin Cash and Flow, each have their own token standards to define their use of NFTs.

WISeKey, the first company in the world to use dual factor authentication combined with blockchain technology to secure luxury watches, currently protects over 2.5 million luxury watches. Since 2010, WISeKey has collaborated with manufactures of luxury watches deploying this unique technology to integrate semiconductors tags powered with its VaultIC154 NFC secure element and provide brands with the ability of:

• issuing a storage device comprising of a digital certificate of authenticity
• checking, when required, the validity of the digital certificate of authenticity
• modifying, when required, the status of validity of the digital certificate of authenticity.
• Dematerialization and creation of a Digital Twin with its corresponded Non–Fungible Token

These tags, when placed on any product and tapped by an NFC phone, securely authenticate, and track the product much like an embedded ePassport and confirm the identity of the product on the blockchain ledger. This technology has received a patent in the USA http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=8&f=G&l=50&co1=AND&d=PTXT&s1=wisekey&OS=wisekey&RS=wisekey  

Furthermore, WISeKey’s technology creates Watch Birth Certificates, digital identities which are analogous to birth certificates and can be converted into NFTs.  The Watch Birth Certificate is signed, or “certified” by a trusted authority and contains basic information such as date & time of manufacture (birth), company (parents), and type of product.  This digital identity, used throughout the watch lifetime, allows the watch to become a “Trusted Object” of the Internet, prove its identity and provide verifiable data.

The Watch Birth Certificate is based on a cryptographic public‑private key pair that is unique to each IoT device.  The public key for this key pair is part of the certificate and can be freely distributed, while the private key is used whenever the IoT device needs to verify its identity or to sign data to ensure cryptographic integrity. It is the private key that represents the essence of the identity of the IoT device.

A WISeKey NFT virtual meeting involving stakeholders on the Art and Luxury Ecosystem will be held on April 14, 2021 at 9:00 am ET https://www.wisekey.com/wisekey-webinar/.

About WISeKey

WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey microprocessors secure the pervasive computing shaping today’s Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.).  WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens.

Our technology is Trusted by the OISTE/WISeKey’s Swiss based cryptographic Root of Trust (“RoT”) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit www.wisekey.com.

Press and investor contacts:

WISeKey International Holding Ltd

Company Contact:  Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
[email protected]        

WISeKey Investor Relations (US)

Contact:  Lena Cati
The Equity Group Inc.
Tel: +1 212 836-9611
[email protected]

Disclaimer:

This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.

• Major expansion of clinical portfolio including initiation of clinical trials with Tedopi^® in ovarian cancer, OSE-127/S95011 in ulcerative colitis, FR104 in renal transplant and an upcoming phase 1/2 for CoVepiT, a multi-variant vaccine against COVID-19.
  
• Positive Tedopi® results for Step-1 of Phase 3 in non-small cell lung cancer post checkpoint inhibitors failure.
• Strong progress on preclinical assets OSE-230, a novel antibody therapeutic promoting the resolution of inflammation, BiCKI^®, a bi-specific platform and CLEC-1 antagonist, a new myeloid “Don’t Eat Me” signal, in immuno-oncology.
  
• Financial visibility extended to Q2 2022 through €18.6 million equity raise in November 2020, €7 million non-dilutive loan guaranteed by the French State in May 2020, €5.2 million granted by Bpifrance for the clinical development of CoVepiT and up to €25 million financing agreement with the European Investment Bank.
  

NANTES, France, March 26, 2021 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2020 and provided an update on key achievements, as well as the Company’s outlook for 2021 for its immunotherapies in T-cell vaccines, immuno-oncology and auto-immunity and inflammation.

Alexis Peyroles, CEO of OSE Immunotherapeutics commented: “2020 was a year of strong achievements and transformation for OSE, creating a clear momentum for the Company’s next phase of growth and reinforcing its status as a key player in immunotherapy. We strengthened and broadened our clinical portfolio with numerous important indications and developed a multi-variant COVID-19 vaccine, parallel to reinforcing our financial position.

Our neoepitope approach with Tedopi^® was validated in the Step-1 of Phase 3 study in non-small cell lung cancer patients after failure of checkpoint inhibitor treatments. This confirms the clinical benefit Tedopi^® can provide to patients who need new therapeutic options for this indication. At the same time, we expand Tedopi^®’s clinical development to ovarian cancer alone and in combination with a checkpoint inhibitor.

Our clinical portfolio made great progress with the launch of clinical trials for three products: a Phase 2 with
IL-7 receptor
antagonist OSE-127/S95011 in ulcerative colitis, a Phase 1/2 with CD28 antagonist FR104 in renal transplant and a Phase 2 to evaluate Tedopi^® alone or combined with Keytruda^® as a maintenance treatment in ovarian cancer. An upcoming Phase 1/2 with CoVepiT, our COVID-19 vaccine, is currently subject to regulatory authorizations.
Our preclinical pipeline has also developed and includes new highly innovative programs such as CLEC-1 and BiCKI^®-IL-7 in immuno-oncology and OSE-230 in the resolution of inflammation.

In parallel, we strengthened our cash position through an equity raise, non-dilutive loans and a COVID-19 specific funding, extending our cash runway to Q2 2022. This strong financial position allows us to further enhance our differentiated and diversified pipeline in immuno-oncology and autoimmune diseases as well as the clinical development of our CoVepiT vaccine.”

2020 KEY ACHIEVEMENTS

Major clinical progress

Tedopi^®,


a combination of 10 neoepitopes


intended


to induce specific T-lymphocyte activation: Positive results of Step-1 Phase 3 in non-small cell lung cancer, initiation of Phase 2 in ovarian cancer

• Positive results for the Step-1 of the ‘Atalante-1’ Phase 3 including benefit in overall survival and good safety profile in non-small cell lung cancer (NSCLC) patients after failure with immune checkpoint inhibitor therapies compared to chemotherapy. Based on these positive data, OSE Immunotherapeutics will engage with U.S. and European health authorities to evaluate the best regulatory strategy for this indication.
• Initiation of a Phase 2 clinical trial, called ‘TEDOVA’, evaluating Tedopi^® in patients with recurrent ovarian cancer. The trial will evaluate Tedopi^® alone and in combination with Merck’s Keytruda^® (pembrolizumab), an immune checkpoint inhibitor relieving the brakes that prevent optimal T lymphocyte activation, compared to best supportive care.
• Tedopi^® is also in a Phase 2 clinical trial for pancreatic cancer patients called ‘TEDOPaM’, sponsored by the GERCOR cooperative group in oncology. Due to the COVID-19 pandemic, accrual of new patients had been temporarily suspended in March 2020. After reviewing data collected until the end of March 2020 and based on the initial protocol (Tedopi^® in combination with Opdivo^® or alone versus chemotherapy by FOLFIRI) trial`s independent committee of scientific experts (IDMC, “Independent Data Monitoring Committee”) recommended to stop the evaluation of treatment with Opdivo^® in combination with Tedopi^® and to integrate the chemotherapy (FOLFIRI) in combination with Tedopi^®. GERCOR has consequently modified the treatment design and the new inclusions (subject to the COVID-19 pandemic impact) are expected in Q2 2021 with an amended protocol comparing Tedopi^® in combination with FOLFIRI chemotherapy versus FOLFIRI, after treatment with FOLFIRINOX. The primary endpoint of the trial remains the one-year survival rate.

CoVepiT

,

a 2



^nd



generation multi-target


vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes: Upcoming initiation of Phase 1/2

• In May 2020, OSE Immunotherapeutics announced its commitment to the fight against COVID-19 with a prophylactic vaccine, named CoVepiT, using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine targets with the lowest chance of natural mutation. CoVepiT demonstrated generation of sentinel memory T cells with long- term protective effect against COVID-19 in preclinical and human ex vivo studies. Targeting 11 virus proteins including Spike, M, N and non-structural proteins, this second-generation vaccine covers all initial and novel SARS-CoV-2 variants identified globally to date.
• OSE will initiate a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of CoVepiT in healthy volunteers and in subjects at risk of severe COVID-19 as soon as it obtains the regulatory authorizations to start the clinical trial.
• Associated with this program, OSE received a grant of up to €200,000 from Nantes Metropole, the metropolitan area of Nantes community (July 2020) and has obtained funding of €5.2 million under the PSPC-COVID call for projects, operated by Bpifrance on behalf of the French Government (December 2020) for the upcoming clinical development in a Phase 1/2.

BI 765063 (OSE-172), a myeloid checkpoint inhibitor being developed in partnership with Boehringer Ingelheim: Ongoing Phase 1

• BI 765063 is in an ongoing Phase 1 clinical trial in advanced solid tumors. The study is a first-in-human dose finding study of BI 765063 administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal PD-1 antibody antagonist, BI 754091, a T lymphocyte checkpoint inhibitor. The trial aims to characterize safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the immunotherapy in patients with advanced solid tumors.

• In October 2020, data supporting additional new mechanism of action for selective antagonist of SIRPα-mediated “Don’t Eat Me” signal BI 765063 were published in the Journal of Clinical Investigation. Based on translational and preclinical studies in rodent in vivo and human ex vivo models characterizing the efficacy and mechanism of action of BI 765063, OSE R&D team has identified a complementary SIRPα-mediated “Don’t Find Me” mechanism by which tumors evade immune detection by preventing T lymphocytes from entering the tumor core. This is the first time this mechanism was identified, and such new anti-SIRPα strategy reverses this major mechanism of resistance named ‘T-cell exclusion’ by releasing the break on T lymphocyte chemotaxis and migration into the heart of the tumors.

OSE-127/S95011, a monoclonal antibody antagonist of the interleukin-7 (IL-7) receptor being developed in partnership with Servier: Initiation of Phase 2 in ulcerative colitis

• In December 2020, the first patient with ulcerative colitis was enrolled in a Phase 2 clinical trial evaluating the efficacy and safety of OSE-127/S95011 versus placebo in patients with moderate to severe active ulcerative colitis who have previously failed, lost response or were intolerant to previous treatment(s). This trial is sponsored by OSE, while Servier is sponsoring a Phase 2a study with OSE-127/S95011 in patients with Sjögren’s syndrome with first enrolled patient now expected by the end of Q2 / early Q3 2021.

• In March 2020, OSE and Servier signed an amendment to the two-step global licensing option agreement for OSE-127/S95011. The 2^nd Step in the option agreement was amended, splitting the €20 million payment from Servier into two. First €5 million milestone payment will be paid upon the enrollment of the first patient in the Phase 2a clinical study in Sjögren’s syndrome. The remaining €15 million will be paid upon exercise of an option at the completion of both Phase 2 clinical trials (the previous version of the agreement had the full €20 million milestone payment due upon completion of Phase 2 clinical study in ulcerative colitis).

FR104, a monoclonal antibody antagonist of CD28: Initiation of Phase 1/2 in renal transplant

• In November 2020, OSE and the Nantes University Hospital announced that the French National Agency for Medicines and Health Products Safety (ANSM), and the French Central Ethics Committee (CPP) approved the initiation of a Phase 1/2 trial evaluating first administration of FR104, a monoclonal antibody CD28 antagonist, in patients undergoing renal transplant. This study will be conducted as part of a collaboration agreement between OSE Immunotherapeutics and the University Hospital of Nantes.

• The purpose of this Phase 1/2 clinical trial, sponsored by the Nantes University Hospital, is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104 in renal transplant patients. A long-term follow up assessment will be performed one year after the end of the study. Long term safety and efficacy will be evaluated in terms of renal function, incidence of rejection and all suspected FR104 related adverse events. 
• Since FR104 showcased a strong development potential in a number of indications, OSE is working in parallel on a new FR104 Phase 2 study in an autoimmune disease indication.

Expansion of preclinical portfolio: novel approaches in cancer immunotherapy and a disruptive concept in the resolution of inflammation

New data on CLEC-1, BiCKI^® and BiCKI-IL-7 presented at the



2020 AACR (American Association of Cancer Research)



Annual Meeting in June 2020 and at the SITC (Society for Immunotherapy of Cancer) in November 2020

• Identification and characterization of a new myeloid checkpoint target CLEC-1 (a C type lectin receptor) and of the first monoclonal antibody antagonists of CLEC-1 blocking the “Don’t Eat Me” signal represent a novel approach in cancer immunotherapy. These findings come from a research program conducted by OSE‘s R&D team in collaboration with Dr. Elise Chiffoleau (Center for Research in Transplantation and Immunology, UMR1064, INSERM, Nantes University at Nantes University Hospital).
• Preclinical progress has confirmed that bispecific platform BiCKI^®, and especially bifunctional therapy targeting PD-1 and IL-7, BiCKI-IL-7, have the potential to overcome resistance mechanisms to anti-PD(L)-1 therapies and could potentially address the needs of a patient population in immune escape from checkpoint inhibitor treatment.

First presentation of new data characterizing OSE-230, the anti-ChemR23 antibody at the FOCIS (Federation of Clinical Immunology Societies) Annual Meeting in October 2020

• Preclinical efficacy results were disclosed for novel agonist monoclonal antibody therapy, OSE-230, in chronic inflammatory preclinical and ex vivo models. The data presented showed that OSE-230 is the first agonist monoclonal antibody triggering the activation of specialized receptors of resolution to restore tissue homeostasis, integrity and functions. These findings provide strong evidence for the therapeutic potential of OSE-230 to be developed in various chronic inflammation and autoimmune pathologies.

2020 FINANCIAL RESULTS

A meeting of the Board of Directors of OSE Immunotherapeutics was held on March 26, 2021 according to the ordinance n° 2020-321 as amended. Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2020.

The key figures of the 2020 consolidated annual results are reported below (and presented in the attached tables):

As of December 31, 2020, the Company’s available cash* amounted to €29.4 million, providing financial visibility to Q2 2022.

In 2020, OSE secured:

• A successful € 18.6 million equity private placement;
• A €7 million non-dilutive loan agreement, with a pool of French banks, guaranteed by the French State.
• A grant of €200,000 from Nantes Metropole, the metropolitan area of Nantes community.

This available cash will be reinforced by:

• A loan facility of up to €25 million from the European Investment Bank (EIB), divided into three tranches including two tranches of €10 million each and a third tranche of €5 million. The first tranche will be drawn before end of May 2021, and a prospectus to be approved by the Autorité des marches financiers will be released prior to the drawdown in relation to the issue of 850,000 warrants to the EIB;
• A €5.2 million funding under the PSPC-COVID call for projects, operated by Bpifrance on behalf of the French Government dedicated to the development of the Company’s prophylactic COVID-19 vaccine CoVepiT;
• €5.1 million of 2020 Research Tax Credit.

These financing enable the Company to support clinical development and R&D costs for earlier stage products until Q2 2022.

During 2020, the Company recorded a consolidated operating loss of (€19) million. Current operating expenses were €29.4 million (€27.4 million in 2019) of which 76% related to R&D. R&D expenses amounted to €22.4 million.

*Available cash and cash equivalents

ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:

Vaccine platform

• Tedopi^® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure.
  In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR)
  In Phase 2 in ovary cancer (TEDOVA, sponsor ARCAGY-GINECO)
  Due to the COVID-19 crisis, accrual of new patients in TEDOPaM should restart in 2021.
• CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results in August 2020, clinical trial expected to start in Q1 2021.

Immuno-oncology platform

• BI 765063 (OSE-172, anti-SIRPα mAb on SIRPα/CD47 pathway): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.
• CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
• BiCKI^®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2^nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.

Auto-immunity and inflammation platform

• FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; ongoing Phase 1/2 in renal transplant, Phase 2-ready asset in a niche indication in autoimmune diseases.
• OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a planned in Sjögren’s syndrome (Servier sponsor).
• OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

For more information:
Click and follow us on Twitter and LinkedIn
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673

Contacts

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2020, including the annual financial report for the fiscal year 2019, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

APPENDICES

CONSOLIDATED PROFIT & LOSS

CONSOLIDATED BALANCE SHEET

CONSOLIDATED CASH FLOW STATEMENT

(1)   
Warrants and free shares awards granted in 2020 and valuated for 1 787 K€

(2)   
Mainly explained by:

• Increase of trade receivable for 327 K€
  
  Increase of other current assets for 2 916 K€
• Increase of trade accounts payable for 3 368 K€
• Increase of social and tax payable for 385 K€
• Decrease of other debts for 3 724 K€

(3)   Explained by IFRS16 application, which corresponds to reimbursement of lease debt for 482 K€

As of December 31, 2020, the available cash is as follows:

Shell International Finance B.V. and Royal Dutch Shell plc

26 March 2021

Publication of Prospectus Supplement

The following documents (the “Documents”) are available for viewing:

Prospectus Supplement dated 23 March 2021

Royal Dutch Shell plc Annual Report for the year ended 31 December 2020

Royal Dutch Shell plc Form 20-F for the year ended 31 December 2020

The Documents must be read in conjunction with the Information Memorandum dated 13 August 2020 as supplemented by the first supplement dated 30 October 2020 relating to the Programme. The Information Memorandum constitutes a base prospectus for the purposes of Regulation (EU) 2017/1129 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Full information on Shell International Finance B.V. and Royal Dutch Shell plc is only available on the basis of the Information Memorandum and the Documents.

To view the Documents, please paste the following URLs into the address bar of your browser.

Royal Dutch Shell plc Annual Report for the year ended 31 December 2020

https://reports.shell.com/annual-report/2020/servicepages/downloads/files/download2.php?file=shell-annual-report-2020.pdf

Royal Dutch Shell plc Form 20-F for the year ended 31 December 2020

https://www.shell.com/about-us/annual-publications/annual-reports-download-centre/_jcr_content/par/tabbedcontent_f645/tab_7bf9_copy/textimage_d83f.stream/1615464115245/a1e527c87e9d548f6e5e0b760ec92c12464b8b94/royal-dutch-shell-form-20-f-2020.pdf

Prospectus Supplement dated 23 March 2021

https://www.shell.com/investors/debt-information/euro-medium-term-note-programme/_jcr_content/par/grid/p0/expandablelist/expandablesection.stream/1616685456469/b8e1a1b767d0ad27ac3ed961ab4de78cbf778bce/shell-supplement-rds-ar-20-f-brexit-march-2021-final.pdf

Other content available on Shell’s website and the content of any other website accessible from hyperlinks on Shell’s website is not incorporated into, and does not form part of, this announcement.

The Documents will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.   

The Information Memorandum is not provided for, or directed at, U.S. persons or persons in the United States. If you are a U.S. person or are viewing this page from the United States, you should exit this section of the website.

For further information, please contact:

Enquiries:

Shell Media Relations
International, UK, European Press: +44 (0)207 934 5550

DISCLAIMER – INTENDED ADDRESSEES

Please note that the information contained in the Information Memorandum may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Information Memorandum) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Information Memorandum is not addressed.  Prior to relying on the information contained in the Information Memorandum, you must ascertain from the Information Memorandum whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

LOS ANGELES, March 26, 2021 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 19, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH) American Depositary Shares (“ADSs”) between December 12, 2019 and February 16, 2021, inclusive (the “Class Period”).

If you suffered a loss on your EHang investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/ehang-holdings-limited/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On February 16, 2021, analyst Wolfpack Research published a research report entitled “EHang: A Stock Promotion Destined to Crash and Burn.” Citing “extensive evidence” including “behind-the-scenes photographs, recorded phone calls, and videos of on-site visits to EH’s various facilities,” the report alleged that EHang is “an elaborate stock promotion, built on largely fabricated revenues based on sham sales contracts with a customer [Shanghai Kunxiang Intelligent Technology Co., Ltd.] who appears to us to be more interested in helping inflate the value of its investment in EH . . . than about buying its products.” Wolfpack Research also noted that “in just 14 months as a publicly traded company, EH’s PR team has put out 50 press releases . . . . However, EH’s constant stream of press releases are easily proven untrue.” Finally, the report alleged that Wolfpack Research “obtained Chinese court records which show that EH’s ADRs may already be in serious jeopardy due to legal issues in China.”

On this news, the Company’s share price fell $77.79, or approximately 62.7%, to close at $46.30 per share, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s purported regulatory approvals in Europe and North America for its EH216 were for use as a drone, and not for carrying passengers; (2) its relationship with its purported primary customer is a sham; (3) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (4) the Company’s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired EHang ADSs  during the Class Period, you may move the Court no later than April 19, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

LOS ANGELES, March 26, 2021 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (“HSAC”, “Immunovant”, or the “Company”) (NASDAQ: IMVT) securities between October 2, 2019 and February 1, 2021, inclusive (the “Class Period”).

If you suffered a loss on your Immunovant investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/immunovant-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (“Legacy Immunovant”) to effect a merger between the two entities (the “Merger”).

Immunovant is developing IMVT-1401, a novel fully human monoclonal antibody, which is Phase IIa clinical trials for the treatment of myasthenia gravis (“MG”) and thyroid eye disease (“TED”). The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (“WAIHA”).

On February 2, 2021, the Company issued a press release “announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.” The Company also disclosed that it “has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low-density lipoproteins] levels in IMVT-1401-treated patients” and “[o]ut of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in [WAIHA], in order to inform patients, investigators, and regulators as well as to modify the monitoring program.”

On this news, the Company’s stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (2) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (3) the foregoing foreseeably diminished IMVT-1401’s prospects for regulatory approval, commercial viability, and profitability; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Immunovant securities during the Class Period, you may move the Court no later than April 20, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com